1. A Profile of Influenza Vaccine Coverage for 2019-2020: a Database Study of the English Primary Care Sentinel Cohort (Preprint)
- Author
-
Uy Hoang, Gayathri Delanerolle, Xuejuan Fan, Carole Aspden, Rachel Byford, Mansoor Ashraf, Mendel Haag, William Elson, Meredith Leston, Sneha Anand, Filipa Ferreira, Mark Joy, Richard Hobbs, and Simon de Lusignan
- Abstract
BACKGROUND Innovation in seasonal influenza vaccine development has resulted in a wider range of formulations becoming available. Understanding vaccine coverage across populations including the timing of administration is important when evaluating vaccine benefit-risk. OBJECTIVE We carried out this study to report the representativeness of the English primary care sentinel cohort (PCSC), the uptake of influenza vaccines, and the different formulations of influenza vaccine and timing of administration within this cohort. METHODS We used the PCSC of the Oxford-Royal College of General Practitioners Research and Surveillance Centre (RSC). We included patients of all ages registered with PCSC member general practices, reporting influenza vaccine coverage between September 1, 2019, and January 29, 2020. We identified influenza vaccination recipients and characterized them by age, clinical risk groups, and vaccine type. We reported date of influenza vaccination within the PCSC by International Standards Organization (ISO) week. The representativeness of the PCSC population was compared with population data provided by the Office for National Statistics (ONS). PCSC influenza vaccine coverage was compared with published UK Health Security Agency’s national data. We used paired t-tests to compare populations, reported with 95% confidence intervals (95% CI). RESULTS The PCSC comprised 7,010,627 people from 693 general practices. The study population included a greater proportion of people aged 18-49 years (42.5% [95% CI 42.5%–42.6%]) compared to the ONS 2019 mid-year population estimates (41.3% [4.12%–41.3%]; P CONCLUSIONS The PCSC’s sociodemographic profile was similar to the national population and captured more data about risk groups, vaccine brand, and batch. This may reflect higher data quality. Its capabilities included reporting precise date of administration. The PCSC is suitable for undertaking studies of influenza vaccine coverage. CLINICALTRIAL This study was classified as a service evaluation (measuring what standard of care this service achieved) by the Medical Research Council/Health Research Authority decision tool [38], so did not require formal ethical approval. It was approved by the RCGP Approval Committee on January 8, 2021.
- Published
- 2022